We found in a Swiss DLBCL cohort that ~15% of patients are projected to respond to the venetoclax/ibrutinib combination based on their high Bcl-2 expression and nuclear NF-κB localization. The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.